Literature DB >> 20482384

Increased serum concentrations of visfatin and its production by different joint tissues in patients with osteoarthritis.

Wei-Ping Chen1, Jia-Peng Bao, Jie Feng, Peng-Fei Hu, Zhong-Li Shi, Li-Dong Wu.   

Abstract

BACKGROUND: The goal of this study was to investigate the distribution of visfatin in paired serum and synovial fluid (SF) samples from patients with osteoarthritis (OA), and in serum from healthy controls. In addition, we wished to determine the potential sources of visfatin in joint tissue.
METHODS: Twenty-three patients with OA requiring total knee arthroplasty (TKA), 17 healthy subjects and ten donors requiring amputation were included in the study. Concentrations of visfatin in serum and SF were analyzed using an enzyme-linked immunosorbent assay (ELISA). The concentration of visfatin was also measured in conditioned media from cultured joint tissues.
RESULTS: We found serum visfatin concentrations to be higher in patients with OA compared to healthy controls (p<0.05), and SF-visfatin concentrations exceeded those in paired serum (p=0.004). In addition, infrapatellar fat pad and synovium were important sources of visfatin, while osteophytes released largest amounts of visfatin. Therefore, osteophytes can be considered a major source of visfatin in the knee joint in patients with OA.
CONCLUSIONS: These results suggest that visfatin may be involved in the pathophysiology of OA and may have local effects in the joint during the process of OA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20482384     DOI: 10.1515/CCLM.2010.230

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  22 in total

1.  Expression of vaspin in the joint and the levels in the serum and synovial fluid of patients with osteoarthritis.

Authors:  Jia-Peng Bao; Li-Feng Jiang; Wei-Ping Chen; Peng-Fei Hu; Li-Dong Wu
Journal:  Int J Clin Exp Med       Date:  2014-10-15

2.  Elevated chemerin levels in synovial fluid and synovial membrane from patients with knee osteoarthritis.

Authors:  Jun Ma; Dong-Sheng Niu; Ning-Jun Wan; Yi Qin; Chong-Jun Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 3.  The current progress in understanding the molecular functions and mechanisms of visfatin in osteoarthritis.

Authors:  Lele Liao; Yiyue Chen; Wanchun Wang
Journal:  J Bone Miner Metab       Date:  2016-03-11       Impact factor: 2.626

4.  Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis.

Authors:  Yuanhui Duan; Dongsheng Hao; Ming Li; Zhihong Wu; Deling Li; Xinyu Yang; Guixing Qiu
Journal:  Rheumatol Int       Date:  2011-01-19       Impact factor: 2.631

5.  Co-culture with infrapatellar fat pad differentially stimulates proteoglycan synthesis and accumulation in cartilage and meniscus tissues.

Authors:  James F Nishimuta; Monica F Bendernagel; Marc E Levenston
Journal:  Connect Tissue Res       Date:  2016-10-11       Impact factor: 3.417

6.  Meniscus is more susceptible than cartilage to catabolic and anti-anabolic effects of adipokines.

Authors:  J F Nishimuta; M E Levenston
Journal:  Osteoarthritis Cartilage       Date:  2015-04-23       Impact factor: 6.576

Review 7.  Adipokines: Biomarkers for osteoarthritis?

Authors:  Thitiya Poonpet; Sittisak Honsawek
Journal:  World J Orthop       Date:  2014-07-18

8.  Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee.

Authors:  Sylvette Bas; Axel Finckh; Gabor J Puskas; Domizio Suva; Pierre Hoffmeyer; Cem Gabay; Anne Lübbeke
Journal:  Int Orthop       Date:  2014-07-09       Impact factor: 3.075

Review 9.  Regulation of energy metabolism in the growth plate and osteoarthritic chondrocytes.

Authors:  Elena V Tchetina; Galina A Markova
Journal:  Rheumatol Int       Date:  2018-07-17       Impact factor: 2.631

10.  Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations.

Authors:  Jeremy Sokolove; Christin M Lepus
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-04       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.